Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance

被引:9
|
作者
Babrzadeh, Farbod [1 ]
Varghese, Vici [2 ]
Pacold, Mary
Liu, Tommy F.
Nyren, Pal [3 ]
Schiffer, Celia [4 ]
Fessel, W. Jeffrey [5 ]
Shafer, Robert W.
机构
[1] Stanford Univ, Stanford Genome Technol Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Med Ctr, Div Infect Dis, Dept Med, Stanford, CA 94305 USA
[3] KTH, AlbaNova Univ Ctr, Dept Biotechnol, Stockholm, Sweden
[4] Univ Massachusetts, Med Ctr, Dept Biochem, Worcester, MA USA
[5] Kaiser Permanente Med Care Program No Calif, Clin Trials Unit, San Francisco, CA USA
关键词
drug resistance; deep sequencing; minority variants; Sanger sequencing; ATAZANAVIR;
D O I
10.1093/jac/dks409
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To determine whether pan-protease inhibitor (PI)-resistant virus populations are composed predominantly of viruses with resistance to all PIs or of diverse virus populations with resistance to different subsets of PIs. We performed deep sequencing of plasma virus samples from nine patients with high-level genotypic and/or phenotypic resistance to all licensed PIs. The nine virus samples had a median of 12 PI resistance mutations by direct PCR Sanger sequencing. For each of the nine virus samples, deep sequencing showed that each of the individual viruses within a sample contained nearly all of the mutations detected by Sanger sequencing. Indeed, a median of 94.9 of deep sequence reads had each of the PI resistance mutations present as a single chromatographic peak in the Sanger sequence. A median of 5.0 of reads had all but one of the Sanger mutations that were not part of an electrophoretic mixture. The collinearity of PI resistance mutations in the nine virus samples demonstrated that pan-PI-resistant viruses are able to replicate in vivo despite their highly mutated protease enzymes. We hypothesize that the marked collinearity of PI resistance mutations in pan-PI-resistant virus populations results from the unique requirements for multi-PI resistance and the extensive cross-resistance conferred by many of the accessory PI resistance mutations.
引用
收藏
页码:414 / 418
页数:5
相关论文
共 50 条
  • [1] HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
    Rhee, Soo-Yon
    Taylor, Jonathan
    Fessel, W. Jeffrey
    Kaufman, David
    Towner, William
    Troia, Paolo
    Ruane, Peter
    Hellinger, James
    Shirvani, Vivian
    Zolopa, Andrew
    Shafer, Robert W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (10) : 4253 - 4261
  • [2] Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance
    Nakashima, Masaaki
    Ode, Hirotaka
    Suzuki, Koji
    Fujino, Masayuki
    Maejima, Masami
    Kimura, Yuki
    Masaoka, Takashi
    Hattori, Junko
    Matsuda, Masakazu
    Hachiya, Atsuko
    Yokomaku, Yoshiyuki
    Suzuki, Atsuo
    Watanabe, Nobuhisa
    Sugiura, Wataru
    Iwatani, Yasumasa
    FRONTIERS IN MICROBIOLOGY, 2016, 7
  • [3] HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
    Fun, Axel
    van Maarseveen, Noortje M.
    Pokorna, Jana
    Maas, Renee E. M.
    Schipper, Pauline J.
    Konvalinka, Jan
    Nijhuis, Monique
    RETROVIROLOGY, 2011, 8
  • [4] HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
    Axel Fun
    Noortje M van Maarseveen
    Jana Pokorná
    Renée EM Maas
    Pauline J Schipper
    Jan Konvalinka
    Monique Nijhuis
    Retrovirology, 8
  • [5] Signature substrate mutations associated with HIV-1 protease inhibitor resistance
    Kolli, M.
    Stawiski, E.
    Chappey, C.
    Parkin, N.
    Schiffer, C. A.
    ANTIVIRAL THERAPY, 2007, 12 : S144 - S144
  • [6] Signature substrate mutations associated with HIV-1 protease inhibitor resistance
    Kolli, M.
    Stawiski, E.
    Chappey, C.
    Parkin, N.
    Schiffer, C. A.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S144 - S144
  • [7] Protease inhibitor resistance in HIV-1 infection
    Resch, W
    Swanstrom, R
    REVIEWS IN MEDICAL MICROBIOLOGY, 2000, 11 (04) : 211 - 221
  • [8] Influence of Major HIV-1 Protease Inhibitor Resistance Mutations on CTL Recognition
    Mueller, Sandra M.
    Spriewald, Bernd M.
    Bergmann, Silke
    Eismann, Kathrin
    Leykauf, Melanie
    Korn, Klaus
    Walter, Hauke
    Schmidt, Barbara
    Arnold, Marie-Luise
    Harrer, Ellen G.
    Kaiser, Rolf
    Schweitzer, Finja
    Braun, Patrick
    Reuter, Stefan
    Jaeger, Hans
    Wolf, Eva
    Brockmeyer, Norbert H.
    Jansen, Klaus
    Michalik, Claudia
    Harrer, Thomas
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 56 (02) : 109 - 117
  • [9] HIV-1 protease inhibitor
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1996, 1 (06) : 261 - 261
  • [10] Low Frequency of Protease Inhibitor Resistance Mutations and Insertions in HIV-1 Subtype C Protease Inhibitor-Naive Sequences
    Ledwaba, Johanna
    Sayed, Yasien
    Pillay, Visva
    Morris, Lynn
    Hunt, Gillian
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2019, 35 (07) : 673 - 678